Engflag

Rinaid

Quick links to important sections

Rinaid

Rinaid_DE

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Jock Itch, Hives, Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rinaid

Property Description
Active ingredient Desloratadine (INN)
Form Tablet, Oral Solution/Syrup, ODT
Pharmacological class Second-generation H1-receptor antagonist
General purpose Symptomatic relief from allergic reactions
Origin Synthetic compound (active metabolite of Loratadine)

Rinaid: Classification and Active Ingredient

Rinaid is a systemic pharmaceutical preparation whose chemical core is the active ingredient Desloratadine (INN), positioning it in the antihistamine class of medicines.

Desloratadine is classified as a second-generation H1-receptor antagonist, a modern synthetic compound that is the major active metabolite of Loratadine. This compound is engineered for selective action primarily on peripheral histamine receptors. Desloratadine exhibits a low potential for penetration into the central nervous system, which supports its non-sedating profile. This ensures the medication provides effective relief without frequently causing the drowsiness often associated with older antihistamines.

What is the General Purpose of Rinaid?

The general purpose of Rinaid is to provide effective, long-acting symptomatic relief by counteracting the disruptive effects of hypersensitivity and allergic reactions.

The drug achieves this through its function as an H1-receptor antagonist: it works by blocking the action of histamine, a substance naturally released by the body that triggers typical allergy symptoms such as sneezing, itching, and a runny nose. By preventing histamine from binding to its designated receptors, Rinaid helps to control the body’s inflammatory response and alleviate the discomfort associated with these allergic manifestations, allowing an individual to manage symptoms during peak allergy seasons.

Available Forms and Product Identity

Rinaid is consistently a single active ingredient product, with Desloratadine as its sole therapeutic component, combined with necessary inert pharmaceutical bases.

This synthetic compound is designed for oral administration for systemic action and is manufactured in several common dosage forms, including the conventional tablet, an oral solution or syrup, and the orally disintegrating tablet (ODT). The availability of liquid and ODT forms makes Rinaid particularly suitable for the pediatric patient group and individuals who have difficulty swallowing tablets, while still maintaining its identity as a convenient, long-acting systemic agent.

What side effects are possible with Rinaid?

Official Safety Profile and Documented Adverse Reactions

The safety profile of Rinaid, based on regulatory documentation, defines potential adverse reactions by frequency and the body system affected. These classifications ensure accurate, label-based communication of risks and are derived from clinical trials and post-marketing surveillance data.

Common Adverse Reactions

The most frequently documented side effects, categorized as Common (affecting between 1 in 10 and 1 in 100 people), include headache, dry mouth, and fatigue.

System-Organ-Class Safety Groupings

Adverse reactions are officially grouped by System-Organ Class (SOC). Documented effects are associated with the Nervous System (e.g., somnolence, dizziness), the Gastrointestinal system (e.g., nausea, abdominal pain), the Hepatobiliary system (e.g., hepatitis, increased liver enzymes), and Cardiac Disorders (e.g., palpitations).

Serious Adverse Reactions

Regulatory sources explicitly list rare but clinically significant adverse reactions, which include severe hypersensitivity events such as anaphylaxis and angioedema. Other serious, very rare reactions documented are seizures, jaundice, and certain cardiac issues, including arrhythmia and QT prolongation.

Population-Specific Safety Considerations and Restrictions

Specific cautions are noted for patients with severe renal or hepatic impairment. The medicine is contraindicated in individuals with known hypersensitivity to the active substance, Desloratadine, or its parent compound, Loratadine. Additionally, official documents note that young children are particularly susceptible to the development of new seizures while under treatment. Although usually non-sedating, individuals should be aware of the potential for somnolence, and caution is recommended regarding co-consumption of alcohol.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Rinaid

Overdose Scope

Documented overdose presentations:

  • The primary reported manifestation in clinical trials, even at high doses (up to nine times the recommended daily dose), is somnolence (drowsiness).
  • Symptoms observed following an overdose may be similar to known adverse events but greater in magnitude.

Physiological systems affected (as stated in label):

  • Central Nervous System (CNS) and Cardiovascular System (in post-marketing reports).

Dose-related or exposure-related factors (if applicable):

  • Symptoms have been observed following ingestion of doses up to 45 mg.

Population-specific overdose notes (if applicable):

  • Pediatric patients are subject to specific safety surveillance notes regarding the potential for severe events, including seizure, arrhythmia, and bradycardia.
  • Patients with hepatic or renal impairment are noted as a special population where the effects may be increased due to slower removal of the drug from the body.

Emergency-response statements (as written in official documents):

  • Symptomatic and supportive treatment is the recommended course of management.
  • Measures to remove the unabsorbed drug from the gastrointestinal tract should be considered.
  • There is no specific antidote known, and the drug and its metabolite cannot be eliminated by hemodialysis.

When immediate medical help is required (label-derived phrasing only):

  • Seek emergency medical attention for any suspected overdose.
  • Call emergency services immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • The documented risk profile ranges from non-severe somnolence to severe systemic events involving the heart and brain.

Regulatory basis (EMA / FDA / etc.):

  • Information is derived from official Prescribing Information and Summary of Product Characteristics (SmPC).

Overdose-context constraints (as defined in official documents):

  • Management is constrained by the lack of a specific reversal agent and the ineffectiveness of hemodialysis for drug removal.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with somnolence and exaggerated effects, and can escalate to severe complications like seizures and cardiac events.
  • Immediate medical attention is required for suspected overdose, and emergency services must be contacted for signs such as collapse or inability to be awakened.
  • Treatment is limited to symptomatic and supportive care due to the lack of a known antidote and ineffective removal by hemodialysis.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by establishing a range of documented effects from exaggerated therapeutic signs to severe systemic risks. Official guidance requires mandatory contact with emergency services for specific, life-threatening clinical signs such as seizure or collapse. Management is strictly defined as supportive care, reflecting the regulatory statement that the drug cannot be effectively removed by established procedures like hemodialysis.

Therapeutic Uses of Rinaid

What Rinaid Treats: Main Uses and Benefits

Rinaid is commonly used to help with conditions presenting with systemic or localized discomfort where symptoms become more noticeable. The medication is relevant when supportive symptom management is appropriate for conditions such as Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria (hives).

Rinaid helps address symptom clusters that may become more noticeable, particularly the nasal-ocular syndrome (sneezing, runny nose, itching, and congestion) and generalized pruritus (itching) that interferes with daily comfort. This offers symptomatic relief that contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Chronic Itching The medicine supports general well-being during symptomatic phases, assisting with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH DailyMed overview on Desloratadine

Eligibility and Restrictions for Use

The eligibility for use of Rinaid is strictly defined by regulatory authorities based on official contraindications and specific patient populations. Use is contraindicated for individuals with a known hypersensitivity or severe allergic reaction to any component of the medication.

Eligibility and Exclusion Rules

Age and Development:

  • Allowed: Use is established for adult and pediatric patients aged 12 years and older.
  • Excluded: Safety and effectiveness have not been established for children under 12 years of age, and its use is not indicated in this population. Nasal corticosteroids, a component of this class, may affect growth velocity in children.

Condition-Specific Restrictions:

  • Contraindicated Conditions: The medicine should not be used in the presence of localized infections of the nose and pharynx caused by Candida albicans (thrush).
  • Avoid Use: Patients who have experienced recent nasal surgery, nasal trauma, or septal ulcers should avoid use until the nasal tissue has fully healed. Corticosteroids may inhibit wound healing.
  • Caution Required: The medicine should be used with caution in patients with active or quiescent tuberculosis, as well as untreated fungal, bacterial, viral, or parasitic infections, including ocular herpes simplex, due to the potential for worsening these conditions. Close monitoring is warranted for patients with a history of glaucoma or cataracts.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rinaid has a high potential for clinically significant drug interactions, which are based on its strong effect as a CYP3A inhibitor and its influence on drug transporters, including P-glycoprotein (P-gp) and OATP1B1.

Contraindicated Combinations

Co-administration with Rinaid is strictly contraindicated under two primary conditions:

  1. Potent CYP3A Inducers: Substances such as St. John's Wort or certain anticonvulsants (e.g., Carbamazepine, Phenytoin) are forbidden as they significantly reduce Rinaid's concentration, leading to a potential loss of efficacy.
  2. Drugs Dependent on CYP3A Clearance: Medications whose elevated exposure is associated with serious and/or life-threatening reactions (e.g., Amiodarone, Flecainide, Simvastatin, Lovastatin).

Pharmacokinetic and Transporter Effects

Mechanism Resulting Interaction Example Co-medication Category
CYP3A Inhibition Increased plasma concentrations HMG-CoA reductase inhibitors, certain antiarrhythmics
P-gp / OATP Inhibition Altered drug exposure Select immunosuppressants, anticoagulants

Population and Timing Constraints

The regulatory profile specifies that Rinaid is not recommended in patients with severe hepatic impairment. For patients with moderate to severe renal impairment, dose modifications or avoidance are required. When initiating Rinaid, the delayed offset of certain potent inducers must be considered, which may require a separation period before Rinaid therapy can safely begin.

Mechanism of Action

Rinaid's mechanism involves two primary, distinct pathways. First, Rinaid acts as an antagonist at the P2Y12 receptor located on the surface of platelets. This binding event initiates the blockade of adenosine diphosphate (ADP)-mediated signaling, thereby modulating platelet activation and subsequent inflammatory cascades.

Secondly, the agent functions as a selective inhibitor of farnesyl diphosphate synthase (FPPS), a key enzyme in the intracellular mevalonate pathway. FPPS inhibition restricts the synthesis of isoprenoid lipids, which are essential for the prenylation of small GTPase signaling proteins. The resulting downregulation of GTPase activity directly impacts the function and cytoskeletal organization of osteoclasts. This cellular effect leads to the suppression of osteoclast maturation and survival, altering the physiological bone remodeling balance toward maintenance of bone structure.

Dosage and Administration Information

Rinaid is an oral pharmaceutical preparation that is used according to specific dosing instructions. The medicine is available in several forms, including film-coated tablets, an oral solution or syrup, and orally disintegrating tablets (ODT), all designed for systemic administration.

Administration Guidelines

Administration Scope Details
Route of administration Oral administration for systemic action.
Standard Dosing Schedule Adults and adolescents (12 years) take 5 mg once daily.
Timing in relation to meals May be taken without regard to meals (with or without food).
Frequency pattern Once daily due to the drug's long duration of action.

Population-Specific Use and Special Handling

The dosing schedule is modified for specific patient populations to ensure proper use:

  • Pediatric Dosing: The daily dose is adjusted by age group: Children 6 to 11 years take 2.5 mg, children 12 months to 5 years take 1.25 mg, and infants 6 to 11 months take 1 mg once daily.
  • Renal/Hepatic Impairment: For adults with diagnosed severe renal or hepatic impairment, the starting dose is reduced to 5 mg every other day.

Administration of the oral solution requires the use of a calibrated measuring device for accuracy. Orally Disintegrating Tablets (ODT) must be removed from their blister packaging immediately prior to use and placed on the tongue, where they dissolve and can be swallowed without water. If a dose is missed, it should be taken as soon as remembered, but the subsequent dose must not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Rinaid

Evidence for use in Seasonal and Perennial Allergic Rhinitis

Research has explored Rinaid's role in conditions like hay fever (seasonal) and year-round allergies (perennial). The core research base consists of short-term, randomized, double-blind trials, where Rinaid was evaluated against a placebo. Studies included adults and adolescents, and examined patient-reported outcomes for physical discomfort (sneezing, runny nose, itching) and measures reflecting daily functioning, such as sleep quality. Follow-up durations were limited, restricting insights into long-term maintenance of symptom control.

Evidence for use in Chronic Idiopathic Urticaria (Hives)

Rinaid was evaluated in intermediate-term controlled trials, typically observing responses over about six weeks, for Chronic Idiopathic Urticaria (hives). Research explored outcomes related to physical discomfort, monitoring outcomes such as the severity of itching (pruritus) and the number and size of the wheals. While research contributes to understanding short-term changes, evidence is limited regarding the modification of the underlying long-term course of the condition.

Long-Term Research and Follow-Up Data

Most pivotal randomized controlled trials were relevant in assessing short-term symptom patterns. Evidence for use over extended periods is primarily derived from observational settings that monitored daily-life functioning and large-scale post-marketing reports. Long-term effects are not fully established by controlled studies, and research highlights what is still uncertain regarding durability of response.

Evidence in Special Populations

Research for allergic rhinitis and chronic hives has also included pediatric populations, starting from infants. In contrast, data for certain groups remain limited. For instance, there is limited information for long-term outcomes in older adults, and research exploring use in people with multiple complex chronic conditions is restricted. The results apply mainly to the populations studied in the primary clinical evaluations.

What is Still Uncertain About Rinaid's Research

Certainty remains low in some areas. One limitation is that comparative evidence is lacking in the form of extensive, direct, head-to-head trials against all other modern antihistamines. Due to the limited information for long-term outcomes, the evidence highlights what is known—and what is still uncertain regarding the maintenance of symptomatic control over years of use.

Frequently Asked Questions (FAQ)

Common questions about Rinaid (FAQ)

Q: How quickly does Rinaid typically start to work after the first dose?

Official product information, supported by clinical studies, indicates that Rinaid begins to show its anti-allergy effects, known as the antihistaminic effect, within one hour after the dose is taken. Clinical studies have shown that the drug's activity can persist for up to 24 hours.

Q: Can Rinaid be taken with common over-the-counter pain medicines like ibuprofen or acetaminophen?

Based on clinical drug interaction studies, there are no known, clinically significant interactions reported when Rinaid is used alongside common over-the-counter pain relievers such as ibuprofen or acetaminophen. The official documentation indicates that no significant interactions have been reported for these combinations.

Q: Is there a generic version of Rinaid available?

Rinaid is based on the active ingredient desloratadine. Regulatory bodies, including the European Medicines Agency (EMA), have approved generic versions of this active ingredient, which are available in various markets.

Q: Does Rinaid require special monitoring or blood tests while taking it?

For most patients, routine blood monitoring or specialized testing is not typically required while using Rinaid. Monitoring may be warranted for patients with severe kidney (renal) or liver (hepatic) impairment, as noted in official documents.

Q: Is Rinaid known to interact with birth control pills?

Clinical studies have not reported significant interactions between Rinaid and oral contraceptives (birth control pills). This information indicates that Rinaid is unlikely to alter the effectiveness or safety profile of these medications.

Q: Does Rinaid have the potential to be habit-forming?

According to official regulatory assessments, Rinaid is not classified as a controlled substance. The active ingredient has no known potential for dependence or abuse.

Q: Is Rinaid a controlled substance?

No, Rinaid is not designated as a controlled substance under the regulatory frameworks of major authorities like the U.S. Controlled Substances Act.

Q: Is Rinaid safe to take during pregnancy?

Regulatory documents state that use of Rinaid during pregnancy is not established. Human studies regarding safety during pregnancy have not been conclusively established, leading to limited regulatory guidance.

Q: What should I do if a side effect seems serious?

Regulatory documents list certain reactions (such as severe allergic symptoms or seizures) as events requiring medical attention. These serious adverse reactions may include symptoms like swelling, difficulty breathing, a fast heart rate, or seizures.

Q: Is it true that Rinaid can cause weight changes?

Post-marketing surveillance, which tracks effects outside of clinical trials, has documented reports of both weight gain and increased appetite as potential adverse reactions. The frequency of these reports is currently classified as 'not known' in regulatory documents.

Q: Can Rinaid affect my blood pressure?

Rinaid is generally not associated with blood pressure changes. However, official safety profiles note that the drug has been linked to fast heart rate (tachycardia) and irregular heartbeats (palpitations) in very rare instances.

Q: What is the maximum duration of treatment with Rinaid usually recommended by regulators?

The recommended duration of treatment often depends on the type of allergy being managed. For allergies that are intermittent, treatment can be stopped when symptoms resolve. For chronic conditions, continuous use may be appropriate, but regulatory bodies do not mandate a fixed, absolute maximum duration for continuous treatment.

Q: What are the official guidelines regarding stopping Rinaid?

For the relief of allergic symptoms, treatment can often be discontinued when the symptoms themselves are resolved. Official documents also indicate that a healthcare provider may decide to discontinue the medicine if a patient, for example, experiences a seizure while taking the drug.

Q: What is the official classification of Rinaid's safety during breastfeeding?

Regulatory information indicates that use of Rinaid while breastfeeding is not recommended. Official product information confirms that Rinaid is excreted into breast milk, meaning the drug can be passed to the infant.

Q: Why is Rinaid only available by prescription?

Rinaid is generally classified as a medicinal product subject to medical prescription. This status is due to its pharmacological profile, safety data, and the need for professional diagnosis and medical oversight, especially for the management of long-term conditions.

How should Rinaid be stored and disposed of?

How to Store and Dispose of Rinaid?

Storage of Rinaid (Desloratadine) must adhere to conditions specified in regulatory labeling to maintain stability. Tablets require storage at Controlled Room Temperature, typically 25 C (77 F), with excursions permitted up to 30 C. The product must be kept in its original, tightly closed container and protected from moisture. The Oral Solution is specifically restricted from freezing and must be protected from light.

Stability and Safety

For the Oral Solution, an in-use limit mandates disposal 2 months after the bottle is first opened. All forms must be stored strictly out of the sight and reach of children.

Disposal

Official instructions prohibit throwing Rinaid away via wastewater or household waste. Unused or expired medication should be disposed of by following the guidance of a pharmacist to comply with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Rinaid found in:

A-Z Index: